Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2025, 169(1):49-55 | DOI: 10.5507/bp.2024.003

Experimental model of primary intraocular lymphoma based on BALB/CaNn strain and A20 cells is optimal for investigational research

Eva Skrlova1, Eva Uherkova1, Aneta Klimova1, Diana Malarikova2, 3, Petra Svozilkova1, Petr Matous4, Vit Herynek4, Tomas Kucera5, Pavel Klener2, 3, Jarmila Heissigerova1
1 Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
2 Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
3 1st Department of Medicine, Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
4 Centre for Advanced Preclinical Imaging, First Faculty of Medicine, Charles University, Prague, Czech Republic
5 Institute of Histology and Embryology, First Faculty of Medicine, Charles University, Prague, Czech Republic

Aim: The purpose of this project was to compare the characteristics of two experimental murine models of primary intraocular lymphoma (PIOL) and determine which experimental model is most suitable for further investigational research to elucidate the pathophysiology of PIOL and to find new therapeutical strategies.

Methods: In both experimental models PIOL was induced in immunocompetent mice with intravitreal injection of syngeneic B-cell lymphoma cell lines. Murine strain C3H/HeN and cell line 38C13 were used in the first model and BALB/CaNn mice and cell line A20 in the second model. During the experiments, thorough clinical evaluation (using photo documentation, ultrasonography, and MRI) and histological evaluation were performed.

Results: In both models, the percentage of PIOL development was high, reaching nearly 80%. Disease progression was faster in C3H/HeN with exophthalmos occurring on average on day 10. Vitreous involvement was a predominant sign in the clinical presentation of this group. In BALB/CaNn mice exophthalmos occurred on average on day 22. The predominant clinical sign in the BALB/CaNn group was tumorous infiltration of the retina, optic disc, and tumorous retinal detachment.

Conclusion: Slower progression of the disease in BALB/CaNn mice, greater possibility to examine the retina due to mild vitreous involvement, and later occurrence of exophthalmos makes this strain more suitable for further investigational research.

Keywords: primary intraocular lymphoma, murine experimental models, A20, 38C13

Received: July 26, 2023; Revised: December 11, 2023; Accepted: February 8, 2024; Prepublished online: February 26, 2024; Published: March 5, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skrlova, E., Uherkova, E., Klimova, A., Malarikova, D., Svozilkova, P., Matous, P., ... Heissigerova, J. (2025). Experimental model of primary intraocular lymphoma based on BALB/CaNn strain and A20 cells is optimal for investigational research. Biomedical papers, 169(1), 49-55. doi: 10.5507/bp.2024.003
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Venkatesh R, Bavaharan B, Mahendradas P, Yadav NK. Primary vitreoretinal lymphoma: prevalence, impact, and management challenges. Clin Ophthalmol 2019;13:353-64. Go to original source... Go to PubMed...
    2. Tang LJ, Gu CL, Zhang P. Intraocular lymphoma. Int J Ophthalmol 2017;10(8):1301-7.
    3. Sagoo MS, Mehta H, Swampillai AJ, Cohen VM, Amin SZ, Plowman PN, Lightman S. Primary intraocular lymphoma. Surv Ophthalmol 2014;59(5):503-16. Go to original source... Go to PubMed...
    4. Klimova A, Heissigerova J, Rihova E, Brichova M, Pytlik R, Spicka I, Mrazova K, Karolova J, Svozilkova P. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse. Br J Ophthalmol 2018;102(11):1579-85. Go to original source... Go to PubMed...
    5. Chan CC, Fischette M, Shen D, Mahesh SP, Nussenblatt RB, Hochman J. Murine model of primary intraocular lymphoma. Invest Ophthalmol Vis Sci 2005;46(2):415-9. doi: 10.1167/iovs.04-0869 Go to original source... Go to PubMed...
    6. Jakša R, Karolová J, Svatoň M, Kazantsev D, Grajciarová M, Pokorná E, Tonar Z, Klánová M, Winkowska L, Maláriková D, Vočková P, Forsterová K, Renešová N, Dolníková A, Nožičková K, Dundr P, Froňková E, Trněný M, Klener P. Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Lab Invest 2022;102(9):957-65. Go to original source... Go to PubMed...
    7. Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res 2017;23(15):4212-23. Go to original source... Go to PubMed...
    8. Rebeaud J, Peter B, Pot C. How Microbiota-Derived Metabolites Link the Gut to the Brain during Neuroinflammation. Int J Mol Sci 2022;23(17):10128. doi: 10.3390/ijms231710128 Go to original source... Go to PubMed...
    9. Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol 2019;16(3):137-54. Go to original source... Go to PubMed...
    10. Aslam H, Green J, Jacka FN, Collier F, Berk M, Pasco J, Dawson SL. Fermented foods, the gut and mental health: a mechanistic overview with implications for depression and anxiety. Nutr Neurosci 2020;23(9):659-71. Go to original source... Go to PubMed...
    11. Dusek O, Fajstova A, Klimova A, Svozilkova P, Hrncir T, Kverka M, Coufal S, Slemin J, Tlaskalova-Hogenova H, Forrester JV, Heissigerova J. Severity of Experimental Autoimmune Uveitis Is Reduced by Pretreatment with Live Probiotic Escherichia coli Nissle 1917. Cells 2020;10(1):23. doi: 10.3390/cells10010023 Go to original source... Go to PubMed...
    12. Li W, Deng Y, Chu Q, Zhang P. Gut microbiome and cancer immunotherapy. Cancer Lett 2019;447:41-7. Go to original source... Go to PubMed...
    13. Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. Integr Cancer Ther 2019;18:1534735419876351. Go to original source... Go to PubMed...
    14. Muraro S, Bondanza A, Bellone M, Greenberg PD, Bonini C. Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. Blood 2005;105(9):3596-3604. Go to original source... Go to PubMed...
    15. Klimova A, Seidler Stangova P, Svozilkova P, Kucera T, Heissigerova J. The Clinical Signs of Experimental Autoimmune Uveitis. Cesk Slov Oftalmol 2016;72(1):276-82. Go to original source... Go to PubMed...
    16. Touitou V, Daussy C, Bodaghi B, Camelo S, de Kozak Y, Lehoang P, Naud MC, Varin A, Thillaye-Goldenberg B, Merle-Béral H, Fridman WH, Sautès-Fridman C, Fisson S. Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci 2007;48(7):3223-9. Go to original source... Go to PubMed...
    17. Seidler Stangova P, Dusek O, Klimova A, Heissigerova J, Kucera T, Svozilkova P. Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis. Folia Biol (Praha) 2019;65(5-6):265-74. Go to original source... Go to PubMed...
    18. Mineo JF, Scheffer A, Karkoutly C, Nouvel L, Kerdraon O, Trauet J, Bordron A, Dessaint JP, Labalette M, Berthou C, Labalette P. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci 2008;49(11):4738-45. Go to original source... Go to PubMed...
    19. Ben Abdelwahed R, Donnou S, Ouakrim H, Crozet L, Cosette J, Jacquet A, Tourais I, Fournès B, Gillard Bocquet M, Miloudi A, Touitou V, Daussy C, Naud MC, Fridman WH, Sautès-Fridman C, Urbain R, Fisson S. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 2013;54(5):3657-65. Go to original source... Go to PubMed...
    20. Gunduz K, Pulido JS, McCannel CA, O'Neill BP. Ocular manifestations and treatment of central nervous system lymphomas. Neurosurg Focus 2006;21(5):E9. Go to original source... Go to PubMed...
    21. Aronow ME, Shen D, Hochman J, Chan CC. Intraocular Lymphoma Models. Ocul Oncol Pathol 2015;1(3):214-22. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content